CHICAGO, April 04, 2017 -- Tempus, a technology company that enables physicians to deliver personalized cancer care, has hired Erik Phelps to serve as Executive Vice President and General Counsel. Phelps will be responsible for a broad range of legal areas for the company, including general corporate matters and strategy. Prior to joining Tempus, Phelps served as General Counsel at Epic, a software company that provides electronic health records for medical groups, hospitals and healthcare organizations. Before that, he served as a partner at Michael Best & Friedrich LLP in Madison, WI where he focused on software licensing and technology related work, including with early-stage companies. He earned his bachelor’s degree from Beloit College and his J.D. from George Washington University Law School.
“Erik spent nearly a decade driving and supporting the growth of one of the largest healthcare technology providers in the world,” said Eric Lefkofsky, Co-founder and CEO at Tempus. “As Tempus continues to scale and partner with large hospital systems and academic centers, we felt it was important to bring on a seasoned leader with strategy and operations experience to accelerate our work to make personalized treatment a reality for patients diagnosed with cancer.”
“Tempus has established itself in short order as an innovator with the potential to transform the industry,” said Phelps, General Counsel at Tempus. “The opportunity to join this data-driven healthcare leader was something that I couldn’t pass up.”
Tempus has recruited a world-class team of accomplished geneticists, computational biologists, data scientists and software engineers who have developed the software and analytic tools that form the foundation of an operating system to battle cancer. The company provides molecular sequencing and clinical analysis for top academic centers, hospital systems, associations, and healthcare providers such as Mayo Clinic, University of Pennsylvania’s Abramson Cancer Center, Northwestern’s Lurie Cancer Center, and the University of Michigan Comprehensive Cancer Center.
About Tempus:
Tempus is a technology company that is building the world’s largest library of molecular and clinical data and an operating system to make that data accessible and useful. We enable physicians to deliver personalized cancer care for patients through our interactive analytical and machine learning platform. We provide genomic sequencing services and analyze molecular and therapeutic data to empower physicians to make real-time, data-driven decisions. Our goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as we gather more data. For more information, visit tempus.com and follow us on Facebook (Tempus Labs) and Twitter (@TempusLabs). For more information on Eric Lefkofsky, visit lefkofsky.com.
Contact: Tempus Clo Ewing Director of Communications [email protected]


Tesla Earnings Beat Expectations as EV Growth Holds Amid Robotics and AI Shift
Organon Stock Surges After Reports of $13 Billion Buyout Bid by Sun Pharma
Elon Musk Signals Intel 14A Chips for Tesla’s Terafab AI Semiconductor Venture
Brazil Pension Fund Crackdown After Banco Master Collapse Raises Investment Concerns
Judge Dismisses Elon Musk’s Fraud Claims Against OpenAI, Trial to Proceed on Remaining Allegations
DeepSeek V4 Launch Signals China’s Growing AI Independence with Huawei Chips
U.S. Raises Alarm Over Chinese AI Firms’ Alleged IP Theft Through Model Distillation
DeepSeek Launches V4 AI Models with Enhanced Reasoning and 1M Token Context Window
European Car Sales Surge in March as EV and Hybrid Demand Accelerates
Florida Launches Criminal Probe Into OpenAI Over FSU Shooting Incident
U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review
Intel Stock Surges as AI Chip Demand Drives Strong Q2 Forecast
Meta Expands AI Training With Employee Activity Tracking Tools
$16B Michigan Data Center Project Boosts U.S. AI Infrastructure Expansion
Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy 



